Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BDX - Becton, Dickinson and Company
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$186.88
DETAILS
HIGH:
$210.00
LOW:
$159.00
MEDIAN:
$190.00
CONSENSUS:
$186.88
UPSIDE:
3.94%
Stock News
BDX DCF Analysis: Intrinsic Value $157 vs Price $187
On September 02, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance with a year-to-date in
Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.
Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”
On a recent edition of CNBC's Mad Money Lightning Round, Jim Cramer fielded questions from viewers. Two of Cramer's clearest calls were to buy Vale (NYSE:VALE | VALE Price Prediction) as an inflation hedge comparable to cryptocurrency and to stay long Apple (NASDAQ:AAPL) through an upcoming leadership change.
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.
BD to Present at Wells Fargo 21st Annual Healthcare Conference
FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.
BDX DCF Analysis: Intrinsic Value $157 vs Price $190
On August 26, 2026, we conducted a DCF analysis for Becton Dickinson and Co (BDX), a company that has shown strong price performance recently with a 1-week increa
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
BDX DCF Analysis: Intrinsic Value $141 vs Price $181
On August 12, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance recently, with a year-to-
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value
On June 30, 2026, First Eagle Investment (Trades, Portfolio) executed a significant add transaction for Becton Dickinson and Co (NYSE: BDX), increasing the firm's
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures
Revenue: $5 billion, up 4.4% on an FX-neutral basis.Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year.Adjusted Gross Margin: 54.3%,
Becton, Dickinson and Company Q3 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
Becton, Dickinson and Co (NYSE:BDX) on Thursday reported third-quarter adjusted earnings of $3.23 per share, beating the consensus of $3.14.
Price Targets
Becton Dickinson price target raised to $190 from $180 at RBC Capital
$190.00
(was $184.04)
RBC Capital
Becton Dickinson price target raised to $195 from $175 at Stifel
$195.00
(was $176.07)
Stifel Nicolaus
Becton Dickinson price target raised to $180 from $175 at RBC Capital
$180.00
(was $176.25)
Shagun Singh
·
RBC Capital
Becton Dickinson price target raised to $210 from $190 at Jefferies
$210.00
(was $176.91)
Jefferies
Becton Dickinson initiated with a Buy at UBS
$190.00
(was $158.92)
UBS
Becton Dickinson price target lowered to $180 from $190 at Evercore ISI
$180.00
(was $154.59)
Evercore ISI
Becton Dickinson price target raised to $204 from $202 at Barclays
$204.00
(was $149.43)
Barclays
Becton Dickinson price target lowered to $159 from $170 at Piper Sandler
$159.00
(was $154.82)
Jason Bednar
·
Piper Sandler
Becton Dickinson price target lowered to $175 from $195 at RBC Capital
$175.00
(was $155.43)
RBC Capital
Becton Dickinson resumed with a Neutral at Goldman Sachs
$167.00
(was $154.42)
David Roman
·
Goldman Sachs
Becton Dickinson price target lowered to $172 from $210 at RBC Capital
$172.00
(was $170.14)
Shagun Singh
·
RBC Capital
Becton Dickinson reinstated with an Overweight at Barclays
$202.00
(was $207.39)
Matt Miksic
·
Barclays
Becton Dickinson price target lowered to $170 from $205 at Piper Sandler
$170.00
(was $207.39)
Piper Sandler
Becton Dickinson price target raised to $205 from $190 at Piper Sandler
$205.00
(was $159.91)
Jason Bednar
·
Piper Sandler
Becton Dickinson price target raised to $215 from $210 at Stifel
$215.00
(was $161.45)
Stifel Nicolaus
Becton Dickinson price target raised to $210 from $202 at RBC Capital
$210.00
(was $154.39)
RBC Capital
Becton Dickinson price target raised to $210 from $197 at Morgan Stanley
$210.00
(was $150.80)
Patrick Wood
·
Morgan Stanley
Becton Dickinson price target lowered to $260 from $280 at Piper Sandler
$260.00
(was $159.06)
Jason Bednar
·
Piper Sandler
Becton Dickinson target raised, added to 'Tactical Outperform' list at Evercore
$290.00
(was $189.54)
Vijay Kumar
·
Evercore ISI
Citi Upgrades Becton Dickinson (BDX) to Buy
$275.00
(was $190.20)
Joanna Wuensch
·
Citigroup